Explore more publications!
Healthcare Today Michigan
Got News to Share?

Healthcare Today Michigan: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Michigan.

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

Press releases published on February 2, 2026

Thérapie révolutionnaire pour l’insuffisance cardiaque avancée
Feb. 2, 2026

Thérapie révolutionnaire pour l’insuffisance cardiaque avancée

Indeterminate GlobeNewswire
Bahnbrechende Therapie für fortgeschrittene Herzinsuffizienz
Feb. 2, 2026

Bahnbrechende Therapie für fortgeschrittene Herzinsuffizienz

Indeterminate GlobeNewswire
Agomab Announces Launch of Initial Public Offering
Feb. 2, 2026

Agomab Announces Launch of Initial Public Offering

Indeterminate GlobeNewswire
Iridex Announces Plans to Relocate Headquarters
Feb. 2, 2026

Iridex Announces Plans to Relocate Headquarters

Indeterminate GlobeNewswire
Guidelight Expands to California with Opening of Los Angeles Clinic
Feb. 2, 2026

Guidelight Expands to California with Opening of Los Angeles Clinic

Indeterminate GlobeNewswire
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
Feb. 2, 2026

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

Indeterminate GlobeNewswire
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
Feb. 2, 2026

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

Indeterminate GlobeNewswire
Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care
Feb. 2, 2026

Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care

Indeterminate GlobeNewswire
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
Feb. 2, 2026

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Indeterminate GlobeNewswire
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Feb. 2, 2026

Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics

Indeterminate GlobeNewswire
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
Feb. 2, 2026

Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

Indeterminate GlobeNewswire
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
Feb. 2, 2026

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

Indeterminate GlobeNewswire
Landmark Living Brain Study Published in CELL Identifies a Novel Molecular Roadmap Governing Human Brain Aging
Feb. 2, 2026

Landmark Living Brain Study Published in CELL Identifies a Novel Molecular Roadmap Governing Human Brain Aging

Indeterminate GlobeNewswire
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
Feb. 2, 2026

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

Indeterminate GlobeNewswire
BrainCo’s Brain-Computer Interface Headband Supporting Social Skills Development in Children with Autism
Feb. 2, 2026

BrainCo’s Brain-Computer Interface Headband Supporting Social Skills Development in Children with Autism

Indeterminate GlobeNewswire
How Consumers Evaluate Mullein Extract Supplements and Drops in 2026: New Research from NUTRAHARMONY
Feb. 2, 2026

How Consumers Evaluate Mullein Extract Supplements and Drops in 2026: New Research from NUTRAHARMONY

Indeterminate GlobeNewswire
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
Feb. 2, 2026

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Indeterminate GlobeNewswire
Communiqué de presse : Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3
Feb. 2, 2026

Communiqué de presse : Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3

Indeterminate GlobeNewswire
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
Feb. 2, 2026

Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease

Indeterminate GlobeNewswire
Every Smile Is Special: Sparkling Charms Dental Studio Highlights Sensory-Friendly Pediatric Dental Program for Children With Special Needs in Baltimore
Feb. 2, 2026

Every Smile Is Special: Sparkling Charms Dental Studio Highlights Sensory-Friendly Pediatric Dental Program for Children With Special Needs in Baltimore

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions